EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Thoracic SMARCA4-deficient undifferentiated tumor: diagnostic characteristics, molecular insights, and treatment approaches

Junmin Song iD, Adam Gersten, Benjamin Herzberg iD, Balazs Halmos iD

The Oncologist · 08.05.2025 · 30 (5)

DOI: 10.1093/oncolo/oyaf121 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Oncologist, online erschienen am 27.05.2025. Verfasst von Junmin Song und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, United States. Hauptthemen laut MEDLINE: DNA Helicases, Nuclear Proteins, Thoracic Neoplasms, Transcription Factors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim, AstraZeneca, Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a newly defined disease entity characterized by aggressive clinical behavior, diagnostic complexity, and poor prognosis. Given its rarity and heterogeneous histological presentation, establishing a definitive diagnosis can be challenging and relies heavily on comprehensive molecular and immunohistochemical evaluation. Here, illustrating the challenges highlighted by a real-world case, we describe the diagnostic pathway leading to SMARCA4-UT identification and discuss the differential diagnosis of thoracic tumors, relevant molecular evaluations, the molecular basis of SMARCA4-UT, and treatment implications. Recognition of this recently described entity is crucial, as an accurate diagnosis—as demonstrated by our case—can guide effective therapy and facilitate enrollment in targeted clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA HelicasesNuclear ProteinsThoracic NeoplasmsTranscription FactorsHumansDiagnosis, Differential

Stichwörter der Autor:innen

BRG1SMARCA4SMARCA4-DTSSMARCA4-UTmediastinal tumor

Substanzen

DNA HelicasesNuclear ProteinsSMARCA4 protein, humanTranscription Factors

Autor:innen und Institutionen

  • Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, United States.
  • Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, United States.
  • Department of Hematology/Oncology, Columbia University, New York, NY 10032, United States.
  • Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, United States.

ORCID-Profile: Junmin Song, Benjamin Herzberg, Balazs Halmos

Förderung

  • Boehringer Ingelheim
  • AstraZeneca
  • Merck
  • Bristol-Myers Squibb
  • Advaxis
  • Amgen
  • AbbVie
  • Daiichi Sankyo

Zitieren

APA

Song, J., Gersten, A., Herzberg, B., & Halmos, B. (2025). Thoracic SMARCA4-deficient undifferentiated tumor: diagnostic characteristics, molecular insights, and treatment approaches. The Oncologist, 30(5). https://doi.org/10.1093/oncolo/oyaf121

Vancouver

Song J, Gersten A, Herzberg B, Halmos B. Thoracic SMARCA4-deficient undifferentiated tumor: diagnostic characteristics, molecular insights, and treatment approaches. The Oncologist. 2025;30(5). doi:10.1093/oncolo/oyaf121

BibTeX
@article{Song2025,
  author = {Song, Junmin and Gersten, Adam and Herzberg, Benjamin and Halmos, Balazs},
  title = {Thoracic SMARCA4-deficient undifferentiated tumor: diagnostic characteristics, molecular insights, and treatment approaches},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {5},
  doi = {10.1093/oncolo/oyaf121}
}
Kostenlos starten →